Literature DB >> 15280124

Foscarnet therapy for congenital cytomegalovirus liver fibrosis following prenatal ascites.

G Nigro1, E Sali, M M Anceschi, M Mazzocco, L Maranghi, A Clerico, M A Castello.   

Abstract

We report on an infant with multi-system disease including liver fibrosis, right microphthalmia with cataract, interstitial pneumonitis, and hyperechoic lesions in the basal ganglia and in the periventricular and thalamic regions. Prenatal ascites with hepatomegaly concomitantly with detection of cytomegalovirus (CMV) DNA in the amniotic fluid, following recurrent maternal CMV infection, had been shown. Although CMV culture and DNA detection were negative in the urine, the infant was given foscarnet because CMV infection was demonstrated in the liver by DNA detection and immunohistochemical staining. Favorable clinical outcome and absence of CMV in the liver were subsequently shown. Our case suggests that congenital CMV disease following maternal recurrence may not be associated with disseminated infection but only with intracellular infection. The diagnosis should therefore be based on CMV detection in the involved organs. Moreover, this is the first report on the possible efficacy and safety of foscarnet for therapy of immunocompetent infants with congenital CMV disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280124     DOI: 10.1080/14767050410001701349

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  3 in total

Review 1.  Safety of alternative antiviral agents for neonatal herpes simplex virus encephalitis and disseminated infection.

Authors:  Yu Wang; Katherine P Smith
Journal:  J Pediatr Pharmacol Ther       Date:  2014-04

Review 2.  Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events.

Authors:  Beth C Marshall; William C Koch
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

3.  Microphthalmia and microcornea: in congenital cytomegalovirus.

Authors:  Maina P Kava; Lakshmi Nagarajan
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.